Voya Investment Management LLC lifted its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 0.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 738,707 shares of the conglomerate’s stock after purchasing an additional 6,701 shares during the quarter. Voya Investment Management LLC’s holdings in Danaher were worth $163,107,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the business. Marquette Asset Management LLC lifted its stake in Danaher by 192.1% in the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after buying an additional 73 shares in the last quarter. N.E.W. Advisory Services LLC acquired a new position in shares of Danaher in the second quarter valued at approximately $25,000. Field & Main Bank bought a new stake in shares of Danaher during the second quarter worth $29,000. Joseph Group Capital Management increased its position in shares of Danaher by 62.4% during the third quarter. Joseph Group Capital Management now owns 151 shares of the conglomerate’s stock worth $33,000 after acquiring an additional 58 shares in the last quarter. Finally, Solstein Capital LLC acquired a new stake in shares of Danaher during the second quarter worth $33,000. 79.05% of the stock is owned by institutional investors.
Insider Buying and Selling at Danaher
In other news, EVP Gregory M. Milosevich sold 2,100 shares of the stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $230.62, for a total transaction of $484,302.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $5,158,277.54. This represents a 8.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Christopher Bouda sold 7,598 shares of the firm’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total value of $1,782,186.88. Following the completion of the transaction, the chief accounting officer owned 9,107 shares of the company’s stock, valued at $2,136,137.92. The trade was a 45.48% decrease in their position. The disclosure for this sale is available in the SEC filing. 10.80% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on DHR
Danaher Price Performance
Shares of DHR opened at $225.56 on Wednesday. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The stock has a market capitalization of $158.69 billion, a P/E ratio of 36.92, a P/E/G ratio of 2.89 and a beta of 0.76. The company has a 50 day moving average of $223.42 and a 200-day moving average of $201.58.
Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The business had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. During the same quarter in the previous year, the firm posted $1.89 earnings per share. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, equities research analysts forecast that Danaher Corporation will post 8.59 EPS for the current fiscal year.
Danaher Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date was Wednesday, September 30th. Danaher’s payout ratio is presently 26.19%.
About Danaher
Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.
Featured Articles
- Five stocks we like better than Danaher
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
